NBIX

152.9432.33%
JO

Jude Onyia

Chief Scientific Officer

Dr. Jude Onyia, Ph.D., serves as Chief Scientific Officer at Neurocrine Biosciences, Inc. since joining on November 29, 2021. He serves as Director at Voyager Therapeutics, Inc. since February 2023. Dr. Onyia was the Chief Scientific Officer at Capsida Biotherapeutics. Prior to that, he spent 25 years at Eli Lilly & Co., beginning as a post-doctoral research fellow and ultimately serving as Vice President of Biotechnology Discovery Research. At Lilly, Dr. Onyia contributed to the discovery and/or advancement of more than 60 clinical candidates across multiple therapeutic areas, which led to seven approved medicines. He also was responsible for more than 50 pre-candidate programs across multiple therapeutic areas. Dr. Onyia serves as Member of Scientific Advisory Board at Maine Institute for Human Genetics and Health since August 2007. Dr. Onyia is also Chief Scientific Leader of integrative technologies at Eli Lilly & Co. in Indianapolis. Dr. Onyia holds a Bachelor of Science degree in Forest Biology from the State University of New York, College of Environmental Science and Forestry, as well as a Ph.D. in Cell and Molecular Biology from the SUNY Health Science Center at Syracuse.

Positions